Cardinal Health, Inc. (CAH) Stock Analysis 2026

HealthcareMedical Distribution
$254.06
as of 2026-10-16
+56.1% (52-week)50D MA $233.00  |  200D MA $214.96

BriMind AI Score

Proprietary
55
Moderate
Price CAGR
15.1%
1Y Return
+51.4%
Analyst Upside
+14.0%
Rev Growth
5.8%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

BriMind 1-Year Price Target

$269.55+6.1% potential
Bear Case
$204.58
Bull Case
$312.45
Model Confidence90%

An even blend of the BriMind AI model's DCF and momentum target ($267.63) and Wall Street's consensus target ($271.47).

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

CAH Revenue & Profitability Breakdown

This chart shows how CAH's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Revenue
$254.25B
Cost of Revenue
-$244.47B
Gross Profit
$9.77B3.8% margin
Operating Expenses
-$6.39B
Operating Income
$3.38B1.3% margin
Tax & Other
-$1.67B
Net Income
$1.71B0.7% margin
Gross Margin
3.8%
Operating Margin
1.3%
Net Margin
0.7%

Key Financial Metrics

Cardinal Health, Inc. trades at a trailing P/E of 32.49x, generates $4.75B in free cash flow, hasn't disclosed a debt/equity ratio, and hasn't disclosed return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Market Cap
$54.55B
P/E (Trailing)
32.49
P/E (Forward)
16.66
PEG Ratio
1.17
Revenue
$254.25B
Revenue Growth
5.8%
Earnings Growth
68.8%
Gross Margin
3.8%
Operating Margin
1.3%
Net Margin
0.7%
Return on Assets
3.7%
Free Cash Flow
$4.75B
Current Ratio
0.88
Quick Ratio
0.42
Beta
0.52
Dividend Yield
0.9%
Payout Ratio
28.3%
Insider Ownership
0.3%
Inst. Ownership
91.0%
Short % Float
3.2%
Book Value / Share
$-12.37

Wall Street Analyst Consensus

Wall Street analysts covering Cardinal Health, Inc. currently haven't converged on a clear consensus rating, with a mean 12-month price target of $270.94 (+6.6% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

Mean Target$270.94+6.6% upside

Technical Price Signals

CAH is currently in a golden cross pattern, trading above its 50-day average of $233.00 and above its 200-day average of $214.96. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

Current Price
$254.06
50-Day MA
$233.00
▲ Price above
200-Day MA
$214.96
▲ Price above
Golden Cross Pattern
Price above both MAs — bullish signal

Compare CAH with Peers

MCK vs CAHMcKesson vs Cardinal Health — Drug Distribution Giants

More Healthcare Stock Analysis

In-depth reports on companies operating alongside CAH — business models, bull and bear cases, and the metrics that matter.

MCKMcKesson CorporationMedical DistributionMRNAModerna, Inc.BiotechnologyNTRANatera, Inc.Diagnostics & ResearchNTLAIntellia Therapeutics, Inc.BiotechnologyDHRDanaher CorporationDiagnostics & ResearchNBIXNeurocrine Biosciences, Inc.Drug Manufacturers - Specialty & GenericCRSPCRISPR Therapeutics AGBiotechnologyJNJJohnson & JohnsonDrug Manufacturers - General

Unlock the Full CAH Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
Data sources: Financial metrics and market data sourced from company SEC filings, earnings releases, and investor relations disclosures. Price data, analyst consensus targets, and fundamental financials provided by financial market data providers. ETF data sourced from official fund prospectuses and index provider publications. AI scores and price targets are proprietary estimates — see our Methodology and Disclaimer for details.
← Back to Home · Browse All Stock Analysis